Table 1.
Demographic and clinical characteristics of the study population.
| Characteristic | Median [Interquartile range] (n) | ||
|---|---|---|---|
| Healthy controls | FEP patients | p value | |
| (n = 22) | (n = 42) | ||
| Gender (M:F) | 11:11 (22) | 27:15 (42) | 0.269a |
| Age (years) | 25.0 [22.0–28.0] (22) | 27.5 [23.0–33.0] (42) | 0.124b |
| BMI (kg m−2) | 21.6 [20.7–23.8] (21) | 22.2 [20.5–25.3] (40) | 0.455b |
| Weight (kg) | 67.9 [61.0–81.8] (18) | 70.2 [62.5–78.3] (40) | 0.658b |
| Length (cm) | 173 [166–185] (19) | 177 [170–181] (40) | 0.759b |
| Tobacco (Y:N) | 0:22; 0% (22) | 12:27; 31% (39) | 0.004a* |
| DUP (months) | – | 4.5 [2.0–18.0] (38) | – |
| Medication (Y:N) | – | ||
| Antipsychotics | – | 18:24; 43% (42) | – |
| Benzodiazepines | – | 12:30; 29% (42) | – |
| Zopiclone | – | 10:32; 24% (42) | – |
| Antidepressants | – | 5:37; 12% (42) | – |
| Phenothiazine derivatives | – | 11:31; 26% (42) | – |
| Antiepileptic’s | – | 1:41; 2,4% (42) | – |
| Combination of > 2 drugs | – | 16:26; 38% (42) | – |
| Totally drug-naive | – | 13:29; 31% (42) | – |
| PANSS | |||
| Positive | – | 19 [15–24] (42) | – |
| Negative | – | 13 [10–19] (42) | – |
| General | – | 38 [31–45] (42) | – |
| Total | – | 75 [60–83] (42) | – |
| Anxiety | – | 4 [3–5] (42) | – |
| Depression | – | 3 [2–4] (42) | – |
| Level of functioning | |||
| GAF S | – | 31 [28–36] (42) | – |
| GAF F | – | 40 [35–50] (42) | – |
| GAF S HVLY | – | 65 [40–75] (39) | – |
| GAF F HVLY | – | 65 [55–79] (39) | – |
| CGI Score | – | 4.0 [3.0–5.0] (42) | – |
Abbreviations: FEP, first-episode psychosis; M:F, Male:Female; Y:N, Yes:No; (n), number; BMI, body mass index; DUP, Duration of untreated psychosis; PANSS, Positive and Negative Syndrome Scale; GAF S, Global Assessment of Functioning Symptoms; GAF F, Global Assessment of Functioning Functions; HVLY, highest value last year; CGI, Clinical Global Impression. aPearson’s chi-squared test bMann-Whitney U-test, two-sided. *p value < 0.05.